ClinicalTrials.gov
public full text
Public Domain
A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
The investigators hope to improve overall median survival of patients with recurrent Glioblastoma by investigating continuous low-dose daily Temozolomide plus or minus five treatments of re-irradiation.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma#1138893
- Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma#1094863
- Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma#1086274
- Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma#668828
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma#6823
Record · ID 1322142
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive